Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,525 shares of the biopharmaceutical company’s stock after acquiring an additional 2,100 shares during the quarter. Regeneron Pharmaceuticals comprises about 0.5% of Y Intercept Hong Kong Ltd’s investment portfolio, making the stock its 12th largest holding. Y Intercept Hong Kong Ltd’s holdings in Regeneron Pharmaceuticals were worth $8,210,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of REGN. Rakuten Securities Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $26,000. Fairfield Financial Advisors LTD bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $37,000. Private Wealth Management Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 39 shares during the period. Finally, Truvestments Capital LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at about $39,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.6 %

REGN opened at $700.33 on Monday. The firm has a market cap of $76.56 billion, a P/E ratio of 18.29, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The business has a 50 day moving average price of $699.40 and a 200 day moving average price of $881.17. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the company earned $11.86 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Analyst Ratings Changes

Several equities research analysts have commented on REGN shares. Oppenheimer dropped their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. TD Cowen reduced their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. Bank of America reiterated an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Robert W. Baird lowered their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.